Art. -Nr.: HY-N1181

Tamarixetin

(Synonyms: 4'-O-Methyl Quercetin)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC₅₀ of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and AKT pathways.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.80%
CAS. Nr.: 603-61-2
Formel: C₁₆H₁₂O₇
Molecular Weight:316.26

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Tamarixetin Chemical Structure

CAS. Nr.: 603-61-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Alle COX Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.63 μM Compound: 3a	Anticancer activity against human A549 cells by HTS assay Anticancer activity against human A549 cells by HTS assay	[PMID: 25139569]
Calu-1	IC₅₀	24.95 μM Compound: 3a	Anticancer activity against human Calu1 cells by HTS assay Anticancer activity against human Calu1 cells by HTS assay	[PMID: 25139569]
HeLa	IC₅₀	1.81 μM Compound: 3a	Anticancer activity against human HeLa cells by HTS assay Anticancer activity against human HeLa cells by HTS assay	[PMID: 25139569]
HOP-62	IC₅₀	9.93 μM Compound: 3a	Anticancer activity against human HOP62 cells by HTS assay Anticancer activity against human HOP62 cells by HTS assay	[PMID: 25139569]
LOX IMVI	IC₅₀	>50 μM Compound: 3a	Anticancer activity against human LOXIMVI cells by HTS assay Anticancer activity against human LOXIMVI cells by HTS assay	[PMID: 25139569]
M14	IC₅₀	14.85 μM Compound: 3a	Anticancer activity against human M14 cells by HTS assay Anticancer activity against human M14 cells by HTS assay	[PMID: 25139569]
Monocyte	IC₅₀	4.6 μM Compound: tamarixetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	4.6 x 10^-6 M Compound: tamarixetin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
NCI-H1299	IC₅₀	21.97 μM Compound: 3a	Anticancer activity against human H1299 cells by HTS assay Anticancer activity against human H1299 cells by HTS assay	[PMID: 25139569]
NCI-H157	IC₅₀	3.04 μM Compound: 3a	Anticancer activity against human NCI-H157 cells by HTS assay Anticancer activity against human NCI-H157 cells by HTS assay	[PMID: 25139569]
NCI-H1792	IC₅₀	4.06 μM Compound: 3a	Anticancer activity against human NCI-H1792 cells by HTS assay Anticancer activity against human NCI-H1792 cells by HTS assay	[PMID: 25139569]
NCI-H1944	IC₅₀	3.86 μM Compound: 3a	Anticancer activity against human NCI-H1944 cells by HTS assay Anticancer activity against human NCI-H1944 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	4.45 μM Compound: 3a	Anticancer activity against human H460 cells by HTS assay Anticancer activity against human H460 cells by HTS assay	[PMID: 25139569]
NCI-H522	IC₅₀	>50 μM Compound: 3a	Anticancer activity against human NCI-H522 cells by HTS assay Anticancer activity against human NCI-H522 cells by HTS assay	[PMID: 25139569]
Peritoneal macrophage	IC₅₀	25 μM Compound: kp21	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
Vero	IC₅₀	170.3 μg/mL Compound: Tamarixetin	Cytotoxicity against african green monkey Vero cells by MTT assay Cytotoxicity against african green monkey Vero cells by MTT assay	[PMID: 18855442]

In Vitro

Tamarixetin (0-100 μM; 0-72 h) is cytotoxic to leukemia cells, inhibits cell proliferation, induces cell apoptosis and cell cycle arrest^[1].
Tamarixetin (0-100 μM; 1 h) inhibits the hypertrophy of H9c2 cells and the production of ROS induced by Phenylephrine (HY-B0769) in a dose-dependent manner^[2].
Tamarixetin (0-25 μM; 30 min) inhibits the secretion of various inflammatory cytokines, promotes the secretion of anti-inflammatory cytokine IL-10, and inhibits the phosphorylation of JNK1, p38 and Akt, COX-2 expression and IκBα degradation in mouse bone marrow dendritic cells treated with LPS (HY-D1056)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

LPS (HY-D1056) treated mouse bone marrow dendritic cells
Concentration:

25 μM
Incubation Time:

30 min
Result:

Inhibited the phosphorylation of JNK1, p38, and Akt, the expression of COX-2, and the degradation of IκBα.

In Vivo

Tamarixetin (0.2% feed management; 6 weeks) improves the myocardial hypertrophy model ^[2].
Tamarixetin (intraperitoneal injection; 1 mg/kg; single dose) has better anti-inflammatory properties, which is related to the increase of the immune cell population secreting IL-10 in mouse models of bacterial septicemia^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Transverse aortic constriction (TAC) mouse model^[2]
Dosage:

0.2%
Administration:

Feed management; 6 weeks
Result:

Alleviated pressure‑overload‑induced cardiac hypertrophy in mice.
Attenuated cardiac fibrosis and apoptosis in pressure‑overloaded hearts.
Suppressed oxidative stress.
Negatively regulated NFAT nuclear translocation level.
Was able to the down-regulate the activation of PI3K/AKT signaling pathway in the heart after pressure overload.

Chemical Information

CAS. Nr. 603-61-2
Appearance Solid
Molecular Weight 316.26
Formel C₁₆H₁₂O₇
Color Yellow to brown
SMILES

O=C1C(O)=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13
Synonyms

4'-O-Methyl Quercetin
Structure Classification
- Flavonoids
- Flavonols
- Phenols
- Polyphenols
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

J Ethnopharmacol

Integrated metabolomics and proteomics analysis elucidated the therapeutic effect of Huangkui Capsule on tacrolimus-induced chronic nephrotoxicity in rats. [Abstract]

2026 Apr 6:360:121196. PMID: 41534748
Bioorg Chem

Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]

2024 Jun:147:107412. PMID: 38696845

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (158.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1620 mL

15.8098 mL

31.6196 mL

5 mM

0.6324 mL

3.1620 mL

6.3239 mL

10 mM

0.3162 mL

1.5810 mL

3.1620 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nicolini F, et al. Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells. Mol Carcinog. 2014 Dec;53(12):939-50. [Content Brief]

[2]. Fan C, et al. Tamarixetin protects against cardiac hypertrophy via inhibiting NFAT and AKT pathway. J Mol Histol. 2019 Aug;50(4):343-354. [Content Brief]

[3]. Park HJ, et al. Tamarixetin Exhibits Anti-inflammatory Activity and Prevents Bacterial Sepsis by Increasing IL-10 Production. J Nat Prod. 2018 Jun 22;81(6):1435-1443. [Content Brief]

[4]. Song W, et al. Tamarixetin Attenuated the Virulence of Staphylococcus aureus by Directly Targeting Caseinolytic Protease P. J Nat Prod. 2022 Aug 26;85(8):1936-1944. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1620 mL	15.8098 mL	31.6196 mL	79.0489 mL
	5 mM	0.6324 mL	3.1620 mL	6.3239 mL	15.8098 mL
	10 mM	0.3162 mL	1.5810 mL	3.1620 mL	7.9049 mL
	15 mM	0.2108 mL	1.0540 mL	2.1080 mL	5.2699 mL
	20 mM	0.1581 mL	0.7905 mL	1.5810 mL	3.9524 mL
	25 mM	0.1265 mL	0.6324 mL	1.2648 mL	3.1620 mL
	30 mM	0.1054 mL	0.5270 mL	1.0540 mL	2.6350 mL
	40 mM	0.0790 mL	0.3952 mL	0.7905 mL	1.9762 mL
	50 mM	0.0632 mL	0.3162 mL	0.6324 mL	1.5810 mL
	60 mM	0.0527 mL	0.2635 mL	0.5270 mL	1.3175 mL
	80 mM	0.0395 mL	0.1976 mL	0.3952 mL	0.9881 mL
	100 mM	0.0316 mL	0.1581 mL	0.3162 mL	0.7905 mL

Tamarixetin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Tamarixetin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Antibacterial Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library